Journal of Adolescent Health
Volume 46, Issue 2, Supplement 2 , Pages S9-S15 , February 2010

Meningococcal Disease Awareness: Clinical and Epidemiological Factors Affecting Prevention and Management in Adolescents

  • Stephen I. Pelton, M.D.

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Stephen I. Pelton, M.D., Maxwell Finland Laboratory for Infectious Diseases, 670 Albany Street, Boston, MA 02118.

Received 9 July 2009 ,Accepted 26 November 2009.

References 

  1. Caugant DA, Tzanakaki G, Kriz P. Lessons from meningococcal carriage studies. FEMS Microbiol Rev. 2007;31:52–63
  2. World Health Organization. WHO fact sheet: Meningococcal meningitis. Available at: http://www.who.int/mediacentre/factsheets/fs141/en/index.html. Accessed May 5, 2009.
  3. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369:2196–2210
  4. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367:397–403
  5. Centers for Disease Control and Prevention. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep. 2007;56:794–795
  6. Hameed R, Riordan FA. Meningococcal disease presenting as bronchiolitis. J Infect. 2002;44:94–95
  7. Kuppermann N, Malley R, Inkelis SH, et al. Clinical and hematologic features do not reliably identify children with unsuspected meningococcal disease. Pediatrics. 1999;103:E20
  8. Granoff D, Harrison L, Borrow R. Meningococcal vaccines. In:  Plotkin S,  Orenstein W,  Offit P editor. Vaccines. 5th edition. Philadelphia, PA: WB Saunders; 2008;p. 399–434
  9. Leonard P, Beattie T. Presenting features of paediatric meningococcal disease–A five year experience from a paediatric accident and emergency department. Health Bull (Edinb). 2000;58:148–151
  10. Wells LC, Smith JC, Weston VC, et al. The child with a non-blanching rash: How likely is meningococcal disease?. Arch Dis Child. 2001;85:218–222
  11. Stephens D, Munford R, Wetzler L. Meningococcal infections. In:  Kasper D,  Braunwald E,  Fauci A, et al. editor. Harrison's Principles of Internal Medicine. 16th edition. New York, NY: McGraw-Hill Professional; 2004;
  12. Wong VK, Hitchcock W, Mason WH. Meningococcal infections in children: A review of 100 cases. Pediatr Infect Dis J. 1989;8:224–227
  13. de Greeff SC, de Melker HE, Schouls LM, et al. Pre-admission clinical course of meningococcal disease and opportunities for the earlier start of appropriate intervention: A prospective epidemiological study on 752 patients in the Netherlands, 2003-2005. Eur J Clin Microbiol Infect Dis. 2008;27:985–992
  14. Finkelman BS, Viboud C, Koelle K, et al. Global patterns in seasonal activity of influenza A/H3N2, A/H1N1, and B from 1997 to 2005: Viral coexistence and latitudinal gradients. PLoS ONE. 2007;2:e1296
  15. Foppa IM, Hossain MM. Revised estimates of influenza-associated excess mortality, United States, 1995 through 2005. Emerg Themes Epidemiol. 2008;5:26
  16. Rosenstein NE, Perkins BA, Stephens DS, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999;180:1894–1901
  17. Shah AP, Smolensky MH, Burau KD, et al. Seasonality of primarily childhood and young adult infectious diseases in the United States. Chronobiol Int. 2006;23:1065–1082
  18. Jansen AG, Sanders EA, Van Der Ende A, et al. Invasive pneumococcal and meningococcal disease: Association with influenza virus and respiratory syncytial virus activity?. Epidemiol Infect. 2008;136:1448–1454
  19. Jensen ES, Lundbye-Christensen S, Samuelsson S, et al. A 20-year ecological study of the temporal association between influenza and meningococcal disease. Eur J Epidemiol. 2004;19:181–187
  20. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med. 2001;344:1378–1388
  21. Kaplan SL, Schutze GE, Leake JA, et al. Multicenter surveillance of invasive meningococcal infections in children. Pediatrics. 2006;118:e979–e984
  22. Centers for Disease Control and Prevention. 2009. Active bacterial core surveillance report, Emerging Infections Program Network: Neisseria meningitidis, provisional 2008. Available at: http://www.cdc.gov/abcs/survreports/mening08.htm. Accessed November 5, 2009.
  23. Goldacre MJ, Roberts SE, Yeates D. Case fatality rates for meningococcal disease in an English population, 1963-98: Database study. BMJ. 2003;327:596–597
  24. MacNeil J. Epidemiology of meningococcal disease in infants and young children. Advisory Committee on Immunization Practices. October 21-22, 2009. Available at: http://www.cdc.gov/vaccines/recs/ACIP/slides-oct09.htm#mv. Accessed November 5, 2009.
  25. Buysse CM, Oranje AP, Zuidema E, et al. Long-term skin scarring and orthopaedic sequelae in survivors of meningococcal septic shock. Arch Dis Child. 2009;94:381–386
  26. Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev. 2007;31:3–14
  27. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2004, through 31 December, 2005. Can Commun Dis Rep. 2007;33:1–15
  28. Informe Regional de SIREVA II. Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis en procesos invasores, 2000-2005. 2007;116–139.
  29. Chiou CS, Liao JC, Liao TL, et al. Molecular epidemiology and emergence of worldwide epidemic clones of Neisseria meningitidis in Taiwan. BMC Infect Dis. 2006;6:25
  30. Coulson GB, von Gottberg A, du Plessis M, et al. Meningococcal disease in South Africa, 1999-2002. Emerg Infect Dis. 2007;13:273–281
  31. European Union Invasive Bacterial Infections Surveillance (EU-IBIS) Network. Invasive Neisseria meningitidis in Europe 2006. Health Protection Agency, London 2006. Available at: www.euibis.org. Updated June 17, 2008. Accessed May 5, 2009.
  32. Lingappa JR, Al-Rabeah AM, Hajjeh R, et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis. 2003;9:665–671
  33. Takahashi H, Kuroki T, Watanabe Y, et al. Characterization of Neisseria meningitidis isolates collected from 1974 to 2003 in Japan by multilocus sequence typing. J Med Microbiol. 2004;53:657–662
  34. Trotter CL, Chandra M, Cano R, et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev. 2007;31:27–36
  35. Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989-1991. MMWR CDC Surveill Summ. 1993;42:21–30
  36. Centers for Disease Control and Prevention. 2009. Active bacterial core surveillance report, Emerging Infections Program Network: Neisseria meningitidis, individual yearly reports. Available at: http://www.cdc.gov/abcs/survreports.htm. Accessed November 5, 2009.
  37. Brooks R, Woods CW, Benjamin DK, et al. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis. 2006;43:49–54
  38. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54:1–21
  39. McNabb SJ, Jajosky RA, Hall-Baker PA, et al. Summary of notifiable diseases–United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;55:1–92
  40. Caugant DA, Hoiby EA, Magnus P, et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol. 1994;32:323–330
  41. Claus H, Maiden MC, Wilson DJ, et al. Genetic analysis of meningococci carried by children and young adults. J Infect Dis. 2005;191:1263–1271
  42. American Academy of Pediatrics Committee on Infectious Diseases. Prevention and control of meningococcal disease: Recommendations for use of meningococcal vaccines in pediatric patients. Pediatrics. 2005;116:496–505
  43. Bruce MG, Rosenstein NE, Capparella JM, et al. Risk factors for meningococcal disease in college students. JAMA. 2001;286:688–693
  44. Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J. 1997;16:979–983
  45. Harrison LH, Dwyer DM, Maples CT, et al. Risk of meningococcal infection in college students. JAMA. 1999;281:1906–1910
  46. Harrison LH, Kreiner CJ, Shutt KA, et al. Risk factors for meningococcal disease in students in grades 9-12. Pediatr Infect Dis J. 2008;27:193–199
  47. Imrey PB, Jackson LA, Ludwinski PH, et al. Outbreak of serogroup C meningococcal disease associated with campus bar patronage. Am J Epidemiol. 1996;143:624–630
  48. Martin DR, Ruijne N, McCallum L, et al. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB. Clin Vaccine Immunol. 2006;13:486–491
  49. Wilder-Smith A, Paton NI, Barkham TM, et al. Meningococcal carriage in Umra pilgrims returning from Saudi Arabia. J Travel Med. 2003;10:147–149
  50. Harrison LH, Pass MA, Mendelsohn AB, et al. Invasive meningococcal disease in adolescents and young adults. JAMA. 2001;286:694–699
  51. Centers for Disease Control and Prevention (CDC). National, state, and local area vaccination coverage among adolescents aged 13-17 years—United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58:997–1001Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5836a2.htmAccessed November 11, 2009
  52. Gray SJ, Trotter CL, Ramsay ME, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: Contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol. 2006;55:887–896
  53. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet. 2004;364:365–367
  54. Balmer P, Borrow R, Miller E. Impact of meningococcal C conjugate vaccine in the UK. J Med Microbiol. 2002;51:717–722
  55. Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet. 2002;359:1829–1831
  56. Bettinger JA, Scheifele DW, Le Saux N, et al. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J. 2009;28:220–224
  57. Larrauri A, Cano R, Garcia M, et al. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine. 2005;23:4097–4100
  58. Steinhoff M. Global epidemiology of meningococcal infections. In:  Nelson K,  Masters Williams C editor. Infectious Disease Epidemiology: Theory and Practice. 2nd edition. Sudbury, MA: Jones and Bartlett; 2007;p. 637–652
  59. Wu HM, Harcourt BH, Hatcher CP, et al. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med. 2009;360:886–892

PII: S1054-139X(09)00644-2

doi: 10.1016/j.jadohealth.2009.11.220

Journal of Adolescent Health
Volume 46, Issue 2, Supplement 2 , Pages S9-S15 , February 2010

Article Tools

* Image Usage & Resolution